

# Gelofusine® vs Geloplasma® in major abdominal surgery

<b>Submission date</b>	<b>Recruitment status</b>	<input checked="" type="checkbox"/> Prospectively registered
11/07/2008	Stopped	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
29/07/2008	Stopped	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
17/04/2019	Surgery	<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Stephen Tricklebank

### Contact details

Guy's and St Thomas' Hospital NHS Foundation Trust  
Anaesthetic Department  
St Thomas' Hospital  
Westminster Bridge Road  
London  
United Kingdom  
SE1 7EH  
+44 20 7188 8768  
stephen.tricklebank@gstt.nhs.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

2008-005175-10

### Protocol serial number

N/A

## Study information

## **Scientific Title**

Volume expansion using a balanced gelatin solution in patients undergoing major abdominal surgery

## **Study objectives**

Null hypothesis: There is no difference in postoperative chloride levels between patients resuscitated with a balanced gelatin solution or a conventional non-balanced gelatin solution.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Awaiting approval by the Guy's and St Thomas' Research Ethics Committee as of 15/07/2008.

## **Study design**

Prospective, randomised, double-blind study

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Volume expansion during major abdominal surgery

## **Interventions**

Patients will be managed perioperatively according to the enhanced recovery protocol, which is well established and constitutes routine practice for all patients undergoing major abdominal surgery at St Thomas' Hospital. Monitoring will be standard plus oesophageal Doppler in all cases. An arterial line will be sited in all patients, usually following induction of anaesthesia. A central venous line will be sited as clinically indicated, usually following induction of anaesthesia. A thoracic epidural will be sited at a level appropriate to the site of surgery. Anaesthesia will be induced as deemed appropriate by the anaesthetist, and maintained with volatile or propofol. Epidural or remifentanil infusions will be used as deemed appropriate by the anaesthetist. This does not deviate from standard practice in our centre.

Colloid will be used intraoperatively to optimise stroke volume, as guided by parameters obtained by oesophageal Doppler.

Patients randomised to the balanced gelatin group will receive Geloplasma® (Fresenius) to optimise stroke volume. Patients randomised to the non-balanced group will receive Gelofusine® (B. Braun Medical Ltd) to optimise stroke volume. In both groups the colloid will be given as a discrete 250 ml bolus, and the change in stroke volume observed. If stroke volume shows a  $\geq 10\%$  rise, the bolus will be repeated until no further rise ( $\geq 10\%$ ) is observed. No further bolus will be given unless stroke volume falls.

Vasoconstrictors will be given if hypotension persists after optimisation of stroke volume. Inotropes will be considered if peak velocity is low and the clinical picture is suggestive of poor ventricular function. In both groups, additional crystalloid solution will be given to replace insensible loss, or as a solvent for drugs. Blood and clotting products will be given as deemed

appropriate by the anaesthetist. Patient temperature will be closely monitored and maintained using a fluid warmer and hot air blanket in all cases. The appropriate colloid will be given in recovery as volume expander as deemed appropriate by the anaesthetist.

Arterial blood samples will be obtained from the arterial cannula after induction of anaesthesia (immediately after insertion, before any colloid is given), at the end of surgery before cessation of controlled ventilation, on arrival in recovery, and after 2 hours in recovery. Presence of postoperative nausea and vomiting (and requirement for rescue antiemetics) will be recorded. Volume of colloid given during surgery will be recorded. Urinary sodium will be measured on insertion of the urinary catheter and after 2 hours in recovery.

Total duration of treatment and follow-up will be for the duration of the operation and for 2 hours in recovery.

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Gelofusine®, Geloplasma®

### **Primary outcome(s)**

The following will be monitored during the surgery and two hours in recovery:

1. Postoperative chloride level
2. Postoperative base excess

### **Key secondary outcome(s)**

The following will be recorded for the duration of surgery, and two hours in recovery:

1. Postoperative pH
2. Volume of colloid given
3. Postoperative renal function
4. Postoperative nausea and vomiting
5. Urinary Sodium
6. Urine output

### **Completion date**

04/05/2009

### **Reason abandoned (if study stopped)**

Lack of funding/sponsorship

## **Eligibility**

### **Key inclusion criteria**

1. Both males and females
2. 18 years or over

3. Patients undergoing major abdominal surgery in the Enhanced Recovery After Surgery programme at Guy's and St Thomas' NHS Foundation Trust, UK
4. American Society of Anaesthesiologists (ASA) grade 1-3

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Known hypersensitivity to Gelofusine® or Geloplasma®
2. Oliguric or anuric renal dysfunction requiring dialysis
3. Estimated glomerular filtration rate (EGFR) <60 ml/min
4. Myocardial infarction within the previous 3 weeks
5. Heart failure (>New York Heart Association [NYHA] class 2)
6. Liver insufficiency (aspartate aminotransferase >40 U/L, alanine aminotransferase >40 U/L)
7. Absence of written, informed consent

**Date of first enrolment**

04/02/2009

**Date of final enrolment**

04/05/2009

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

Guy's and St Thomas' Hospital NHS Foundation Trust

London

United Kingdom

SE1 7EH

# Sponsor information

## Organisation

Guy's and St Thomas' NHS Foundation Trust (UK)

## ROR

<https://ror.org/00j161312>

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

Guy's and St Thomas' NHS Foundation Trust, Department of Anaesthesia (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes